FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biochemistry and represents an isolated human or humanised antibody or its functional fragment which is specific to human GM-CSF. Also, there are presented variable heavy and light chains of the antibody, isolated nucleic acid sequences, an expression vector, a host cell, a pharmaceutical composition and a method of treating a GM-CSF-related condition.
EFFECT: invention may be used for treating the GM-CSF-related diseases for the diagnostic purposes, as well as for further studying of the GM-CSF role in progression of various diseases.
102 cl, 21 dwg, 8 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| OSTEOARTHRITIS TREATMENT | 2009 |
|
RU2712273C2 |
| ANTIBODY AGAINST PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) AND APPLICATION THEREOF | 2015 |
|
RU2661678C1 |
| ANTI-CXCR4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | 2014 |
|
RU2675516C2 |
| HUMAN ANTI-CD38-ANTIBODIES AND THEIR APPLICATION | 2005 |
|
RU2402568C2 |
| MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3 | 2019 |
|
RU2777336C1 |
| PAIN TREATMENT | 2009 |
|
RU2712166C2 |
| PAIN TREATMENT | 2009 |
|
RU2630969C2 |
| ISOLATED ANTI-CD30 ANTIBODY (VERSIONS); HOST CELL, METHOD OF OBTAINING CHIMERIC OR HUMANISED VERSION OF ANTI-CD30 ANTIBODIES (VERSIONS), METHOD OF INHIBITING GROWTH OF CELLS CD30+ AND METHOD OF INHIBITING GROWTH OF TUMOUR CELLS EXPRESSING CD30 | 2006 |
|
RU2492186C2 |
| HUMANIZED ANTI-C5 ANTIBODIES AND THEIR APPLICATION | 2019 |
|
RU2792237C2 |
| ANTIBODIES TO MST1R AND THEIR APPLICATION | 2010 |
|
RU2534890C2 |
